智通财经网·2025-09-15 09:40Core Viewpoint - The company, Zhaoyan New Drug (06127), announced that its A-share stock experienced a cumulative price fluctuation exceeding 20% over three consecutive trading days, which is classified as an abnormal trading situation according to the Shanghai Stock Exchange rules [1]. Group 1: Production and Operational Status - The company confirmed that its production and operational activities are normal, and there have been no significant changes in the internal or external operating environment that would affect the stock price [1]. Group 2: Major Events - A self-examination by the company and inquiries with its controlling shareholders revealed no major events that could impact the stock price, including significant asset restructuring, share issuance, acquisitions, debt restructuring, asset divestiture, or asset injection [2]. Group 3: Media Reports and Market Rumors - The company has not identified any media reports or market rumors that require clarification or response, nor have there been any other significant events that could substantially affect the stock price [3]. Group 4: Other Price-Sensitive Information - The company verified that there were no transactions involving its controlling shareholders, actual controllers, directors, supervisors, or senior management during the period of abnormal stock price fluctuations [4].